Dai-ichi Life Group has confirmed that its Australian subsidiary submitted a non-binding proposal to the board of Challenger Limited, but says it has made no decision to pursue a legally binding transaction.
What the company confirmed
In a notice dated October 19, 2026, headed "regarding certain media reports", the Tokyo-listed insurer (TSE Prime, code 8750) addressed press coverage of a possible share acquisition. The reports said TAL Daiichi Life Australia Pty Limited, which the company calls its Australian subsidiary and abbreviates as TDA, had submitted a non-binding proposal on acquiring shares in Challenger. Challenger is listed on the Australian Securities Exchange (ASX: CGF). The notice names its chief executive and managing director as Nick Hamilton.
The company states that the reports were not announced by it. It does, however, confirm the core point: TDA has submitted a non-binding proposal to Challenger's board of directors.
What remains undecided
The notice says that, at this point, the company has not decided anything on proceeding with a legally binding transaction. In other words, the confirmed step is a proposal to the target's board, not an agreed deal or a tender offer.
The notice gives no price, share count, structure or financing terms, and does not describe how Challenger's board has responded. Readers should treat any figures that appear in press coverage as outside the company's own statement.
The next disclosure trigger
Dai-ichi says it will disclose matters "in a timely and appropriate manner" if any fact that should be made public is decided. The practical marker to watch is therefore a decision by the company to move toward a binding transaction, which the notice says has not happened.